Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Quick test in your doctor's office could fight serious lung infections

NCT ID NCT07159230

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This study tests whether a rapid PCR test done right in the clinic can help doctors diagnose and treat acute respiratory infections faster. Over 16,000 adults at risk of severe illness will take part. The goal is to see if this approach lowers rates of respiratory failure and hospitalization.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
point-of-care multiplex PCR test
What this could lead to
If successful, this test could help doctors quickly identify the cause of respiratory infections and give the right treatment sooner, potentially reducing hospitalizations and severe illness.
What could go wrong
This is a large trial but still early in real-world use. The test may not always be accurate or change outcomes significantly, and results depend on how well clinics follow the guidance.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 16,868 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Sep 2025

An estimate. Start dates often move.

Expected to finish

Jan 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Onset time\<=7 days; 2. First visit; 3. Age\>=18 years old; 4. Patients with acute upper respiratory tract infection with severe high-risk factors, or patients with acute lower respiratory tract infection; 5. The condition is allowed to be treated in an outpatient clinic; 6. Signed informed consent. Exclusion Criteria: 1. The doctor judges that the disease is serious and requires hospitalization; 2. New unclear consciousness; 3. Respiratory rate\>=30 beats/min; 4. Hypoxemia or respiratory failure; 5. Heart rate\> 125 beats/min; 6. Systolic blood pressure \< 90 or diastolic blood pressure \< 60 mmHg; 7. Known active tuberculosis; 8. Pregnant and lactating women; 9. Have participated in this study within 90 days;

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Acute respiratory tract infection are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Xincheng District Hospital, Hohhot; Genghis Khan Community Health Service Center; East Street & West Street Sub-district Community Health Service Center; East Yingxin Road Community Health Service Center and so on

    Hohhot, Inner Mongolia, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.